The Road to DTx Reimbursement: Lessons from PECAN & LPPR
The French combination of temporary reimbursement during evidence development (PECAN) with a route to permanent reimbursement (LPPR) provides one of the most attractive pathways for digital therapeutics.
๐ก Understanding PECAN
PECAN offers Digital Health companies reimbursement for their digital health device during a defined period while they generate the required clinical evidence. This gives companies a crucial opportunity to secure early revenues.
The PECAN process is specifically designed to align with the requirements needed to transition to permanent reimbursement through the LPPR process.
โ Challenges in Securing Reimbursement
๐ซ Unfortunately, no DTx has yet secured reimbursement in France, with four negative assessments issued by HAS for applications submitted through PECAN.
๐ These results highlight the rigorous standards set by HAS and emphasize the critical need for robust clinical evidence to achieve reimbursement.
For DTx developers, understanding these challenges is crucial to refining their strategies and successfully navigating the process.
๐ What Youโll Learn
Curious why no DTx have been approved so far? Want to learn about common pitfalls and how to optimize your approach?
๐ Join us for our webinar on March 20th! Weโll explore the evolving DTx landscape in France, share key lessons from the initial PECAN assessments, and provide actionable strategies to improve your chances of success.
๐ Register Now